The Cytotron® is a non-invasive whole-body therapeutic device that is a breakthrough in tissue engineering.

The Cytotron® is a stand-alone device based on Rotational Field Quantum Magnetic Resonance (RFQMR) platform technology that enables whole body therapeutics called Quantum Magnetic Resonance Therapy (QMRT). QMRT is the Cytotron® device-mediated, an innovative therapeutic modality for tissue Degeneration (for Cancer) and Regeneration (for human degenerative disease indications), currently in the clinical stage of development in the US. The Cytotron® operates at the safe end of the Electromagnetic Spectrum, and therapeutic signals are lower than microwave and cellphone frequencies.

RFQMR Technology in a nutshell

In 1987, the Centre for Advanced Research and Development (CARD), initiated a project to study the effect of modulated radio frequency (RF) in the safe, unexplored frequency band of 30kHz to 300MHz

The high powered, rotational field, multi-frequency, high energy, spinning, quantum electromagnetic resonating beams can “engineer” tissues and modulate cell control

This novel treatment modality is registered as Quantum Magnetic Resonance Therapy (QMRT®)

Pain Relief & Palliation is integral to RFQMR platform technology and QMRT

Cytotron Facts

The Cytotron® has been clinically validated since 2004

European Union CE Mark-Certified for use in Musculoskeletal Disorders and Cancer (since 2012)

Clinical study in Multiple Sclerosis (MS) initiated and registered

Awarded US Patent - US9162076B2 European Patent - EP1753508B1 Chinese Patent - CN1960779B

Cost effective with minimal infrastructure and maintenance costs

More than 30 commercial and private installations world-wide

Tissue Degeneration – Cancer

On October 24th 2019, the Cytotron was granted Breakthrough Device Designation by the U.S. FDA for Breast, Liver, and Pancreatic Cancers. (LINK) Additional solid tumor indications of use and other life-limiting indications are being pursued in parallel.

The Cytotron® device delivers rotating, target-specific, modulated, safe Radio Frequencies in the presence of a pulsed, integrated, instantaneous magnetic field. The presumed modulation of the transmembrane potential of tumor cells and downstream cellular signaling by RF for tissue degeneration in cancer underlies Rotational Field Quantum Magnetic Resonance platform technology. Whole-body MRI for tissue proton density determinations is used to compute individualized dosimetry to target solitary or multiple regions of interest in the whole body, simultaneously. Exposure to QMRT is for 1 hour daily for 28 consecutive days. Quality of Life assessments, overall survival, and tumor stability endpoints have shown remarkable improvement over standard of care related treatment outcomes (see publication in a peer-reviewed journal in Resources).


Cytotron for the Pediatric Brain Tumor Clinical Trial at National Children’s Hospital (HIM) in Mexico City